New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

3 September 2020
Updated results published today in the prestigious New England Journal of Medicine herald the long-term effectiveness of a targeted combination drug therapy given after surgery in patients with high risk early melanoma.
The international study reports that in patients with Stage III BRAF-positive melanoma who were treated with adjuvant targeted therapy, there can be a long-lasting benefit from the treatment in preventing the disease from recurring.
In the Phase III trial, known as COMBI-AD, patients were treated with either a combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) or placebo given after surgery. The trial demonstrated early promising results after 12 months of treatment and significantly improved recurrence-free survival.
This latest publication revealed the effects of treatment have continued to be sustained after five years. In patients who received the combination therapy, 52% had no disease recurrence after five years. By comparison, only 36% of those patients on placebo – which was the standard of care at the time - had no disease recurrence during this time.
“Our research has demonstrated that many patients have long-term benefit on adjuvant combination targeted therapy, and it may be curative in most of those patients,” says co-senior author and Co-Medical Director of Melanoma Institute Australia Professor Georgina Long AO.
The study shows that adjvuant targeted therapy for patients with the BRAF mutation prevents recurrence in high-risk stage III melanoma.
“Melanoma Institute Australia is working closely with our international collaborators to take major steps forward in cancer treatment,” says Professor Long. “These results take us even closer to reaching our goal of zero deaths from melanoma this decade.”
Journal publication:
Reinhard Dummer, M.D., Axel Hauschild, M.D.,Mario Santinami, M.D., Victoria Atkinson, M.D., Mario Mandalà, M.D., John M. Kirkwood, M.D., Vanna Chiarion Sileni, M.D., James Larkin, M.D., Ph.D., Marta Nyakas, M.D., Caroline Dutriaux, M.D., Andrew Haydon, M.B., B.S., Ph.D., Caroline Robert, M.D., Ph.D., Laurent Mortier, M.D., Ph.D., Jacob Schachter, .D., Thierry Lesimple, M.D., Ruth Plummer, M.D., Kohinoor Dasgupta, Ph.D., Eduard Gasal, M.D., Monique Tan, M.D., Georgina V. Long, M.B., B.S., Ph.D., and Dirk Schadendorf, M.D.
(2020) Five-Year Relapse-Free Survival With Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutant Melanoma. NEJM.
Read online here.

A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Professor Georgina Long hands on baton of SMR Presidency
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

City2Surf 2020
Join in the fun of the virtual event, and together we can run over melanoma!

Top melanoma experts at MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Top melanoma experts from MIA
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Melanoma Supportive Care Needs research study.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

New online melanoma risk calculators critical to saving lives
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Professor Richard Scolyer receives University of Sydney Alumni Award.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Uniting together despite the distance
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Important Update: Masks required at Poche Centre
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.